Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:44 AM
Ignite Modification Date:
2025-12-25 @ 1:44 AM
NCT ID:
NCT03774394
Eligibility Criteria:
Inclusion Criteria:
* Type 2 DM, defined according to ADA definition, on treatment with oral hypoglycemic agents and/or insulin
* Angiographically documented CAD
* On treatment with low-dose aspirin (81mg/day) for ≥30 days as part of standard of care.
Exclusion Criteria:
* Use of any antiplatelet therapy (except aspirin) in prior 30 days
* Use of parenteral or oral anticoagulation
* Active bleeding
* High risk of bleeding
* Clinical indication to be on a P2Y12 receptor inhibitor
* End-stage renal disease on hemodialysis
* Any active malignancy
* Platelet count \< 100x106/µl
* Hemoglobin \<9 g/dl
* Severe known liver disease
* Hemodynamic instability
* Known allergy to clopidogrel
* Pregnant / lactating females (women of childbearing age must use reliable birth control).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03774394
Study Brief:
Protocol Section:
NCT03774394